Professor (Adjunct) Graham Kelly

Co-Founder, CEO and Managing Director

BSc (Vet) (Hons), BVSc (Hons), PhD

Graham brings to Filamon a lifetime career in cancer research, drug development, entrepreneurial skills and a wealth of public company corporate experience spanning three decades in Australia, U.K. and U.S.

Graham had 25 years of cancer research in the Faculty of Medicine, University of Sydney before founding the following companies:

• Novogen Ltd (now Kazia Therapeutics) (Nasdaq: KZIA) listed 1994
• MEI Pharma Inc (Nasdaq: MEIP) listed 2002
• Noxopharm Ltd (ASX: NOX) listed 2016
• Nyrada Inc (ASX: NYR) listed 2020.